ArticleEuropean journal of neurology2022
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
Article in European journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Association between vaccination and myasthenia gravis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Small fiber neuropathy associated with COVID-19 infection and vaccination: A prospective case-control study.European journal of neurology · 2025Article
- Myasthenia gravis and community-acquired pneumonia: therapeutic challenges.Frontiers in pharmacology · 2025Review
- First Paediatric Case of mRNA COVID-19 Vaccine Associated New Onset Systemic Myasthenic Crisis.Sisli Etfal Hastanesi tip bulteni · 2025Article
- Patient-reported daily functioning after SARS-CoV-2 vaccinations in autoimmune neuromuscular diseases.European journal of neurology · 2024Observational
- The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis.Vaccines · 2024Article
- The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection.Brain and behavior · 2024Article
- COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Observational
- Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis.Heliyon · 2024Article
- Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients.Journal of inflammation research · 2024Article
- Association between COVID-19 and myasthenia gravis (MG): A genetic correlation and Mendelian randomization study.Brain and behavior · 2023Article
- Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Myasthenia gravis, respiratory function, and respiratory tract disease.Journal of neurology · 2023Review
- COVID-19 vaccination in myasthenia gravis: safe, but predictors of disease exacerbation yet to be determined.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A follow-up study.European journal of neurology · 2023Article
- Clinical Characteristics of Myasthenia Gravis Patients with COVID-19 in Guangxi, China: A Case-Control Study.Journal of inflammation research · 2023Article
- Vaccination against COVID-19 does not lead to exacerbation in patients with myasthenia gravis.Muscle & nerve · 2023Article
- Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeDuring the COVID-19 pandemic, myasthenia gravis (MG) patients have been identified as subjects at high risk of developing severe COVID-19, and thus were offered vaccination with priority. The lack of direct data on the safety and tolerability of SARS-CoV-2 vaccines in MG have contributed to vaccine hesitancy. To address this issue, the safety and tolerability of SARS-CoV-2 vaccines were assessed in a large cohort of MG patients from two referral centers.
methodsPatients with confirmed MG diagnosis, consecutively seen between October and December 2021 at two MG centers, were enrolled. Demographics, clinical characteristics, and information regarding SARS-CoV-2 infection/vaccination were extracted from medical reports and/or collected throughout telephonic or in-person interviews.
resultsNinety-eight (94.2%) of 104 patients included were administered at least two vaccine doses 4 weeks before the interview or earlier, and among them, 63 of 98 (64.2%) have already received the "booster" dose. The most frequently used vaccines were BNT162b2-Pfizer-BioNTech and mRNA-1273-Moderna. Overall, only minor side effects were reported, most commonly local pain and fever. MG worsening after vaccination was observed in eight of 104 (7.7%) cases. The frequency of worsening among muscle-specific tyrosine kinase MG cases (3/9, 33.3%) was significantly higher compared to other serological subgroups. Spontaneous symptom regression was observed in six of eight cases. Twelve of 104 (11.5%) patients had SARS-CoV-2 infection, and none of the SARS-CoV-2-infected MG patients worsened after vaccination.
conclusionsOur data support the safety and tolerability of mRNA COVID-19 vaccines, which should be strongly recommended in MG patients, who could be at higher risk of complications if exposed to SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.